11:51 AM EST - RepliCel Life Sciences Inc. : Announced that the first three participants in the phase 1 clinical trial (NCT02391935) evaluating its RCS-01 product have been enrolled, and their tissue biopsies sent for processing prior to intra-dermal injections. RepliCel Life Sciences Inc.
shares V.RP are trading up $0.02 at $0.37.
